1. Home
  2. INAB vs CDLX Comparison

INAB vs CDLX Comparison

Compare INAB & CDLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$0.75

Market Cap

11.8M

Sector

Health Care

ML Signal

HOLD

Logo Cardlytics Inc.

CDLX

Cardlytics Inc.

HOLD

Current Price

$1.03

Market Cap

10.1M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
INAB
CDLX
Founded
2016
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
11.8M
10.1M
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
INAB
CDLX
Price
$0.75
$1.03
Analyst Decision
Strong Buy
Hold
Analyst Count
3
4
Target Price
★ $7.00
$4.43
AVG Volume (30 Days)
★ 69.2K
60.7K
Earning Date
11-05-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 50.13
EPS
★ N/A
N/A
Revenue
N/A
★ $233,273,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$12.53
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.72
$0.55
52 Week High
$2.73
$6.40

Technical Indicators

Market Signals
Indicator
INAB
CDLX
Relative Strength Index (RSI) 32.88 23.58
Support Level N/A $0.85
Resistance Level $1.50 $1.16
Average True Range (ATR) 0.08 0.17
MACD -0.01 -0.03
Stochastic Oscillator 9.62 9.57

Price Performance

Historical Comparison
INAB
CDLX

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

About CDLX Cardlytics Inc.

Cardlytics Inc is a commerce media platform that is designed to make commerce smarter and rewarding for everyone. At the core of its commerce media platform is the financial media network that it runs within its partners' digital channels, which includes online and mobile applications (the Cardlytics platform). Additionally, it operates an identity resolution platform that utilizes point-of-sale (POS) data, including product-level purchase data, to enable marketers to perform analytics and targeted loyalty marketing and also measure the impact of their marketing (the Bridg platform). It operates in three segments: the Cardlytics platform in the U.S.; the Cardlytics platform in the U.K.; and the Bridg platform. The majority of the revenue is derived from the Cardlytics platform.

Share on Social Networks: